Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 25/100

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights – BIOA

Key Takeaway: BioAge Labs, Inc. is currently facing a securities fraud class action lawsuit related to its lead product candidate, azelaprag. The lawsuit follows the company's announcement on December 6, 2024, that it would discontinue the STRIDES Phase 2 trial due to safety concerns that surprised investors, resulting in a significant stock price drop. Shareholders who purchased shares during the class period are encouraged to register for participation in the lawsuit before the March 10, 2025 deadline.

Market Sentiment Analysis

CONCERNS & RISKS

  • BioAge's stock price dropped significantly after discontinuation of the STRIDES Phase 2 trial.
  • Safety concerns over elevated liver transaminase levels led to halted trials, impacting investor confidence.
  • The lawsuit stems from potential misleading statements during the IPO about azelaprag's efficacy.

Full Press Release Details

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).
Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024.
ALLEGATIONS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
DEADLINE: March 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=125522&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BIOA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 10, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for the BioAge Labs lawsuit?

The class period extends to shareholders who bought stock related to BioAge’s IPO on or about September 26, 2024.

What caused BioAge's stock price decline?

The stock dropped after BioAge announced the discontinuation of the STRIDES Phase 2 trial due to safety concerns on December 6, 2024.

When is the deadline to register for the class action?

Shareholders must register by March 10, 2025, to participate in the class action.

Do I need to be a lead plaintiff to recover losses?

No, being appointed as lead plaintiff is not necessary to participate in the recovery.

How can shareholders monitor the case's progress?

Registered shareholders will receive updates through a portfolio monitoring software during the case.

Last updated: Jan 29, 2025